Search Results - "Lassen, Ulrik N"

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy by Kummar, Shivaani, Lassen, Ulrik N.

“…Oncogenic somatic chromosomal rearrangements involving the NTRK1 , NTRK2 or NTRK3 genes ( NTRK gene fusions) occur in up to 1% of all solid tumors, and have…”
Get full text

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib by Yang, James C H, Brose, Marcia S, Castro, Gilberto, Kim, Edward S, Lassen, Ulrik N, Leyvraz, Serge, Pappo, Alberto, López-Ríos, Fernando, Reeves, John A, Fellous, Marc, Penault-Llorca, Frédérique, Rudzinski, Erin R, Tabatabai, Ghazaleh, Vassal, Gilles, Drilon, Alexander, Trent, Jonathan

“…Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers…”
Get full text

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children by Drilon, Alexander, Laetsch, Theodore W, Kummar, Shivaani, DuBois, Steven G, Lassen, Ulrik N, Demetri, George D, Nathenson, Michael, Doebele, Robert C, Farago, Anna F, Pappo, Alberto S, Turpin, Brian, Dowlati, Afshin, Brose, Marcia S, Mascarenhas, Leo, Federman, Noah, Berlin, Jordan, El-Deiry, Wafik S, Baik, Christina, Deeken, John, Boni, Valentina, Nagasubramanian, Ramamoorthy, Taylor, Matthew, Rudzinski, Erin R, Meric-Bernstam, Funda, Sohal, Davendra P.S, Ma, Patrick C, Raez, Luis E, Hechtman, Jaclyn F, Benayed, Ryma, Ladanyi, Marc, Tuch, Brian B, Ebata, Kevin, Cruickshank, Scott, Ku, Nora C, Cox, Michael C, Hawkins, Douglas S, Hong, David S, Hyman, David M

“…Fusions involving tropomyosin receptor genes are noted in cancers affecting children and adults. The TRK inhibitor larotrectinib induced a response in 75% of…”
Get full text

Precision oncology: a clinical and patient perspective by Lassen, Ulrik N, Makaroff, Lydia E, Stenzinger, Albrecht, Italiano, Antoine, Vassal, Gilles, Garcia-Foncillas, Jesus, Avouac, Bernard

“…Molecular characterization of tumors has shifted cancer treatment strategies away from nonspecific cytotoxic treatment of histology-specific tumors toward…”
Get full text

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas by Kummar, Shivaani, Shen, Lin, Hong, David S, McDermott, Ray, Keedy, Vicki L, Casanova, Michela, Demetri, George D, Dowlati, Afshin, Melcón, Soledad Gallego, Lassen, Ulrik N, Leyvraz, Serge, Liu, Tianshu, Moreno, Victor, Patel, Jyoti, Patil, Tejas, Mallick, Atrayee Basu, Sousa, Nuno, Tahara, Makoto, Ziegler, David S, Norenberg, Ricarda, Arvis, Pierre, Brega, Nicoletta, Drilon, Alexander, Tan, Daniel S W

“…Larotrectinib, a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with…”
Get full text

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers by Drilon, Alexander, Tan, Daniel S W, Lassen, Ulrik N, Leyvraz, Serge, Liu, Yongmei, Patel, Jyoti D, Rosen, Lee, Solomon, Benjamin, Norenberg, Ricarda, Dima, Laura, Brega, Nicoletta, Shen, Lin, Moreno, Victor, Kummar, Shivaani, Lin, Jessica J

“…Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion-positive…”
Get more information

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors by Meulendijks, Didier, Jacob, Wolfgang, Martinez-Garcia, Maria, Taus, Alvaro, Lolkema, Martijn P, Voest, Emile E, Langenberg, Marlies H G, Fleitas Kanonnikoff, Tania, Cervantes, Andres, De Jonge, Maja J, Sleijfer, Stefan, Soerensen, Morten Mau, Thomas, Marlene, Ceppi, Maurizio, Meneses-Lorente, Georgina, James, Ian, Adessi, Celine, Michielin, Francesca, Abiraj, Keelara, Bossenmaier, Birgit, Schellens, Jan H M, Weisser, Martin, Lassen, Ulrik N

“…A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a…”
Get full text

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity by Meulendijks, Didier, Jacob, Wolfgang, Voest, Emile E, Mau-Sorensen, Morten, Martinez-Garcia, Maria, Taus, Alvaro, Fleitas, Tania, Cervantes, Andres, Lolkema, Martijn P, Langenberg, Marlies H G, De Jonge, Maja J, Sleijfer, Stefan, Han, Ji-Youn, Calles, Antonio, Felip, Enriqueta, Kim, Sang-We, Schellens, Jan H M, Wilson, Sabine, Thomas, Marlene, Ceppi, Maurizio, Meneses-Lorente, Georgina, James, Ian, Vega-Harring, Suzana, Dua, Rajiv, Nguyen, Maitram, Steiner, Lori, Adessi, Celine, Michielin, Francesca, Bossenmaier, Birgit, Weisser, Martin, Lassen, Ulrik N

“…This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized, glycoengineered, anti-HER3 monoclonal…”
Get full text

Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib by Kummar, Shivaani, Berlin, Jordan, Mascarenhas, Leo, van Tilburg, Cornelis M., Geoerger, Birgit, Lassen, Ulrik N., Schilder, Russell J., Turpin, Brian, Nanda, Shivani, Keating, Karen, Childs, Barrett H., Chirila, Costel, Laetsch, Theodore W., Hyman, David M., Drilon, Alexander, Hong, David S.

“…Neurotrophic tyrosine receptor kinase (NTRK) gene fusions lead to chimeric tropomyosin receptor kinase (TRK) fusion proteins, which act as primary oncogenic…”
Get full text

A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers by Lassen, Ulrik N, Meulendijks, Didier, Siu, Lilian L, Karanikas, Vaios, Mau-Sorensen, Morten, Schellens, Jan H M, Jonker, Derek J, Hansen, Aaron R, Simcox, Mary E, Schostack, Kathleen J, Bottino, Dean, Zhong, Hua, Roessler, Markus, Vega-Harring, Suzana M, Jarutat, Tiantom, Geho, David, Wang, Ka, DeMario, Mark, Goss, Glenwood D

“…Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) and fibroblast growth factor-inducible molecule 14 (Fn14) are a ligand-receptor pair…”
Get full text

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors by Meulendijks, Didier, Lassen, Ulrik N, Siu, Lillian L, Huitema, Alwin D R, Karanikas, Vaios, Mau-Sorensen, Morten, Jonker, Derek J, Hansen, Aaron R, Simcox, Mary E, Schostack, Kathleen J, Bottino, Dean, Zhong, Hua, Roessler, Markus, Vega-Harring, Suzana M, Jarutat, Tiantom, Geho, David, Wang, Karen, DeMario, Mark, Goss, Glenwood D, Schellens, Jan H M

“…The TWEAK-Fn14 pathway represents a novel anticancer target that is being actively investigated. Understanding the relationship between pharmacokinetics of…”
Get full text

CTNI-07. LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN UPDATED ANALYSIS by Perreault, Sébastien, Spano, Jean-Philippine, Nilsson, Anna, Deyell, Rebecca J, Doz, François, Geoerger, Birgit, Gumus, Mahmut, Lassen, Ulrik N, Nysom, Karsten, Valero-Arrese, Lorena, Idbaih, Ahmed, Bernard-Gauthier, Vadim, Neu, Natascha, Brega, Nicoletta, Drilon, Alexander, Laetsch, Theodore W, van Tilburg, Cornelis M

“…Abstract BACKGROUND Larotrectinib is a highly selective TRK inhibitor approved for TRK fusion tumor-agnostic use. We report updated data on…”
Get full text

CTNI-62. LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS by Perreault, Sébastien, Drilon, Alexander, Lassen, Ulrik N, Geoerger, Birgit, Nysom, Karsten, Øra, Ingrid, Gavrilovic, Igor T, Norenberg, Ricarda, Bernard-Gauthier, Vadim, De La Cuesta, Esther, Laetsch, Theodore W, Doz, François, Van Tilburg, Cornelis M

“…Abstract BACKGROUND Larotrectinib is a highly selective TRK inhibitor that demonstrated an objective response rate (ORR) of 30% and a 24-week disease control…”
Get full text

Abstract CT199: Larotrectinib in TRK fusion cancer patients: Outcomes by prior therapy and performance status by Drilon, Alexander, van Tilburg, Cornelis M., Farago, Anna F., Kummar, Shivaani, Berlin, Jordan, Albert, Catherine M., McDermott, Ray, Lassen, Ulrik N., Reeves, John A., Brega, Nicoletta, Childs, Barrett H., Laetsch, Theodore W., Hong, David S.

“…Abstract Introduction: Larotrectinib, a highly selective Food and Drug Administration- and European Medicines Agency-approved TRK inhibitor, achieved an…”
Get full text

CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES by Patel, Jyoti D, Farago, Anna F, Hong, David S, Lassen, Ulrik N, Leyvraz, Serge, Park, Keunchil, Sohal, Davendra P S, Solomon, Benjamin, Reeves, John A, Dima, Laura, Brega, Nicoletta, Drilon, Alexander

“…Abstract BACKGROUND NTRK gene fusions occur in a range of tumor types, including those with CNS metastases. Larotrectinib, a highly selective FDA- and EMA-…”
Get full text

Outcome of combination chemotherapy in extensive stage small-cell lung cancer: Any treatment related progress? by Lassen, Ulrik N, Hirsch, Fred R, Østerlind, Kell, Bergman, Bengt, Dombernowsky, Per

“…During the past two decades many different treatment regimens of combination chemotherapy have been applied in extensive stage small-cell lung cancer (SCLC)…”
Get full text

Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions in larotrectinib (laro) clinical trials by Rudzinski, Erin R., Ladanyi, Marc, Ritterhouse, Lauren L., Sahm, Felix, Norenberg, Ricarda, Zheng, Hong, Chen, Chi, Bernard-Gauthier, Vadim, Brega, Nicoletta, van Tilburg, Cornelis M., Lin, Jessica J., Brose, Marcia S., Lassen, Ulrik N., McDermott, Ray, Laetsch, Theodore W., Hong, David S., Drilon, Alexander, Roy-Chowdhuri, Sinchita

“…Abstract Background: NTRK gene fusions are oncogenic drivers in various tumor types. Laro, a highly selective and central nervous system (CNS)-active…”
Get full text

Abstract CT545: Variability in NTRK gene fusions does not appear to impact response to larotrectinib by Ladanyi, Marc, Roy-Chowdhuri, Sinchita, Ritterhouse, Lauren, Sahm, Felix, Norenberg, Ricarda, Shen, Kui, Chen, Chi, Fellous, Marc, Brega, Nicoletta, van Tilburg, Cornelis M., Lin, Jessica J., Brose, Marcia S., Lassen, Ulrik N., McDermott, Ray, Laetsch, Theodore W., Hong, David S., Drilon, Alexander, Rudzinski, Erin R.

“…Abstract Introduction: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Gene fusions arise from inter-…”
Get full text

A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously intreated small cell lung cancer and extensive disease by Lassen, Ulrik N., Sorensen, Morten, Jensen, Peter Buhl, Langer, Seppo W., Jensen, Britta Bjerregaard, Jeppesen, Nina, Rytter, Carsten, Mellemgaard, Anders, Hansen, Olfred, Osterlind, Kell

Get full text